These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 37259575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah ND.
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N.
    Circulation; 2018 Apr 03; 137(14):1450-1459. PubMed ID: 29133607
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123
    [Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
    Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N.
    Diabetes Obes Metab; 2018 Nov 15; 20(11):2585-2597. PubMed ID: 29938883
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Arbel R, Aboalhasan E, Hammerman A, Azuri J.
    Am J Cardiol; 2021 Jul 01; 150():65-68. PubMed ID: 34001339
    [Abstract] [Full Text] [Related]

  • 11. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
    Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M.
    Eur J Heart Fail; 2024 Jul 01; 26(7):1539-1548. PubMed ID: 38745498
    [Abstract] [Full Text] [Related]

  • 12. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
    Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E.
    Circulation; 2021 Feb 23; 143(8):770-779. PubMed ID: 33302723
    [Abstract] [Full Text] [Related]

  • 13. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.
    Circulation; 2019 May 28; 139(22):2528-2536. PubMed ID: 30882238
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV.
    Cardiovasc Diabetol; 2023 Mar 10; 22(1):54. PubMed ID: 36899387
    [Abstract] [Full Text] [Related]

  • 15. Can we go beyond surrogates?
    Drexler A.
    J Diabetes; 2017 Nov 10; 9(11):976-977. PubMed ID: 28692750
    [Abstract] [Full Text] [Related]

  • 16. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N.
    Circulation; 2021 Feb 09; 143(6):516-525. PubMed ID: 33186500
    [Abstract] [Full Text] [Related]

  • 17. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators.
    N Engl J Med; 2019 Nov 21; 381(21):1995-2008. PubMed ID: 31535829
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
    Desai RJ, Glynn RJ, Everett BM, Schneeweiss S, Wexler DJ, Bessette LG, Déruaz-Luyet A, Vedin O, Brodovicz K, Patorno E.
    Am Heart J; 2022 Dec 21; 254():203-215. PubMed ID: 36150454
    [Abstract] [Full Text] [Related]

  • 19. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, Salsali A, Kaempfer C, Brueckmann M, Pocock SJ, Januzzi JL, Packer M.
    Eur Heart J; 2022 Sep 21; 43(36):3435-3446. PubMed ID: 35788657
    [Abstract] [Full Text] [Related]

  • 20. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun 21; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.